Table 5.
|
MPH dose level |
Effect of MPH dose level |
|
|||||
---|---|---|---|---|---|---|---|---|
CGI measure: Mean/SD (Clinician) | Placebo | Low dose MPH | Medium dose MPH | High dose MPH | ANOVA p-value | Linear trend p-value | Quadratic trend p-value | Source of significance |
CGI-Severity (DAP) | 4.8 | 4.0 | 3.8 | 3.8 | 0.000 | 0.001 | 0.018 | P:L, P:M, P:H |
(0.61) | (0.81) | (0.82) | (0.74) | |||||
CGI-Improvement (DAP) | 4.0 | 2.8 | 2.4 | 2.1 | 0.000 | 0.000 | 0.126 | P:L, P:M, P:H |
(0.81) | (1.3) | (1.3) | (1.2) | |||||
CGI-Severity (CWS) | 4.7 | 4.0 | 4.0 | 3.9 | 0.000 | 0.001 | 0.086 | P:L, P:M, P:H |
(0.76) | (0.72) | (0.62) | (0.74) | |||||
CGI-Improvement (CWS) | 4.1 | 2.8 | 2.6 | 2.0 | 0.000 | 0.000 | 0.218 | P:L, P:M, P:H |
(0.95) | (1.4) | (1.3) | (1.0) |
Bold indicates that there was a statistically significant effect of MPH dose (i.e., p < .05).
P, placebo; L, low dose MPH; M, medium dose MPH; H, high dose MPH.